Demonstration campaign scheduled to produce more than 100 kg beginning in April
BERKELEY, Calif., Mar. 31, 2021 — Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced the launch of a commercial-scale production campaign for its Lygos CBx cannabinoid business beginning in April 2021. After successfully transferring and piloting its novel fermentation-based production pathway, Lygos is now focused on running multiple production campaigns throughout 2021 to meet growing customer demand.
“We have completed this important milestone on our way to providing high-quality, traceable, and natural cannabinoids at a scale relevant to the consumer-packaged goods sector,” stated Eric Steen, PhD, CEO of Lygos. “Our depth of expertise in developing novel technology and proven ability to produce sustainable ingredients enables us to commercialize new products faster than ever before. Importantly, the modularity we have designed into our cannabinoid platform allows us to quickly adapt to the evolving market and react to the developing demand for our products, starting with CBG (cannabigerol) and CBC (cannabichromene) and extending to a broader range of cannabinoids.”
Lygos CBx’ bio-based production platform features quality control measures to ensure its products reproducibly meet high-quality standards with each batch and production site. To date, internal production capabilities have allowed kilogram quantities of cannabinoid products to be developed, tested, and qualified for Lygos’ partners. The upcoming fermentations will be conducted at the 10,000 L scale and are expected to yield more than 100 kg of high-purity cannabinoid products, including CBG, CBC, CBD (cannabidiol), and CBDA (cannabidiolic acid). This production campaign will support new and existing commercial relationships and will be followed by larger production campaigns later in the year at a significantly larger capacity.
“Over the past year, Lygos developed and scaled the CBx technology at an incredibly rapid pace,” said Nick Ohler, PhD, CTO of Lygos. “Despite the enormous challenges of COVID preventing travel and requiring an entirely remote process transfer to the new site, the scaleup has been smooth and almost entirely as expected, which speaks to the skill of our technical team and the robustness of our process.”
Lygos will continue to expand its portfolio of available cannabinoid products and plans on launching a suite of cannabinoid-based consumer products within the year. Lygos will also continue to co-develop cannabinoid-based products with other industry-leading companies such as High Beauty, Open Book Extracts, and MetaLabs.
About Lygos CBx
Lygos CBx is a Lygos company focused on low-cost, industrial-scale production of a wide range of high-quality, pure and sustainable cannabinoid compounds that are not easily accessible through traditional agricultural means. The cannabinoids are designed to enhance numerous consumer products, as well as health & wellness and pharmaceutical applications. For more information, visit cbx.lygos.com.
Lygos has created a full-stack biological engineering platform focused on organic acid specialty ingredients, health & wellness ingredients, including cannabinoids and bio-monomers. Lygos’ sustainable, bio-based chemicals replace expensive, environmentally degrading alternatives from traditional industrial suppliers, enabling customers to create better, safer products with value-added performance. For more information, visit www.lygos.com and follow us @LygosBiotech.
Lygos, Lygos CBx, and the Lygos and Lygos CBx logos are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.